Validated high-conviction buyer — this insider’s opportunistic purchases fall in a cohort whose buys have historically preceded above-benchmark moves. How we measure this ↗
Director Lucchese buys 125,000 shares for $1.875M on day of IPO; 4 insiders buying in same window.
Lucchese Cynthia L, a director of Mobia Medical, purchased 125,000 shares at the IPO price on the company's first trading day as part of a broader wave of insider buying—four insiders bought open-market shares within a two-week window. This represents her second open-market purchase in the 36-month tracking window, following a prior buy that subsequently declined; her historical track record shows purchases that have not appreciated after acquisition. The timing is notable: she is buying at the IPO price itself rather than waiting for secondary trading, and the cluster of director-level purchases on the opening trading day is unusual. Without longer trading history or financial fundamentals available, the significance of this trade depends on how Mobia's stock performs after listing and whether this wave of director purchases reflects underlying confidence in the company's prospects or merely represents pre-planned IPO allocations.
Director Cynthia Lucchese buys 1,784 shares of COO at $84.06; 4 other insiders bought within 14 days
Lucchese purchased 1,784 shares at $84.06, increasing her holdings from 7,661 to 9,445 shares. This transaction occurred as part of a cluster pattern in which 4 other insiders also purchased shares within the past 14 days, suggesting coordinated or independently motivated acquisitions at similar valuations. The purchase price of $84.06 sits above the current price of $82.88 and well below the 52-week high of $99.45. With a P/E of 41.65, the stock trades at a premium multiple; the 90-day price movement of +21.3% indicates recent momentum ahead of this transaction. The multi-insider buy cluster is a notable signal of insider activity concentration during this period.
